MediWound Ltd. Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million

Reuters

2025/05/21

<a href="https://laohu8.com/S/MDWD">MediWound Ltd.</a> Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million

MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, reported its financial results for the first quarter ending March 31, 2025. The company achieved a revenue of $4 million for the quarter. MediWound has reaffirmed its full-year 2025 revenue guidance at $24 million, indicating confidence in its financial outlook. In addition to the financial results, MediWound provided updates on its operations, highlighting the advancement of the VALUE Phase III trial of EscharEx® for venous leg ulcers as planned. Furthermore, the expansion of NexoBrid® manufacturing remains on schedule, with full operational capacity expected by the end of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455683-en) on May 21, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537982379"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537982379\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537982379?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537982379","market":"us","top_or_hot":-1,"title":"MediWound Ltd. Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDWD\">MediWound Ltd.</a> Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, reported its financial results for the first quarter ending March 31, 2025. The company achieved a revenue of $4 million for the quarter. MediWound has reaffirmed its full-year 2025 revenue guidance at $24 million, indicating confidence in its financial outlook. In addition to the financial results, MediWound provided updates on its operations, highlighting the advancement of the VALUE Phase III trial of EscharEx® for venous leg ulcers as planned. Furthermore, the expansion of NexoBrid® manufacturing remains on schedule, with full operational capacity expected by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455683-en) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediWound Ltd. Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediWound Ltd. Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDWD\">MediWound Ltd.</a> Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, reported its financial results for the first quarter ending March 31, 2025. The company achieved a revenue of $4 million for the quarter. MediWound has reaffirmed its full-year 2025 revenue guidance at $24 million, indicating confidence in its financial outlook. In addition to the financial results, MediWound provided updates on its operations, highlighting the advancement of the VALUE Phase III trial of EscharEx® for venous leg ulcers as planned. Furthermore, the expansion of NexoBrid® manufacturing remains on schedule, with full operational capacity expected by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455683-en) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDWD","symbol_name":"MediWound Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL1bVWGb:1","article_id":"2537982379","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537982379","pubTimestamp":1747825237,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, reported its financial results for the first quarter ending March 31, 2025. The company achieved a revenue of $4 million for the quarter. MediWound has reaffirmed its full-year 2025 revenue guidance at $24 million, indicating confidence in its financial outlook. In addition to the financial results, MediWound provided updates on its operations, highlighting the advancement of the VALUE Phase III trial of EscharEx for venous leg ulcers as planned. Furthermore, the expansion of NexoBrid manufacturing remains on schedule, with full operational capacity expected by the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original conte","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MDWD":"MediWound Ltd.","NDAQ":"纳斯达克OMX交易所"},"translate_title":"MediWound Ltd.报告2025年第一季度收入为400万美元；重申全年收入指引为2400万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"MDWD":0.9},"content_text":"MediWound Ltd. Reports Q1 2025 Revenue of $4 Million; Reaffirms Full-Year Revenue Guidance at $24 Million\n    \n\n        MediWound Ltd., a leader in enzymatic therapeutics for tissue repair, reported its financial results for the first quarter ending March 31, 2025. The company achieved a revenue of $4 million for the quarter. MediWound has reaffirmed its full-year 2025 revenue guidance at $24 million, indicating confidence in its financial outlook. In addition to the financial results, MediWound provided updates on its operations, highlighting the advancement of the VALUE Phase III trial of EscharEx® for venous leg ulcers as planned. Furthermore, the expansion of NexoBrid® manufacturing remains on schedule, with full operational capacity expected by the end of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9455683-en) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}